Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CVM Offices

CVM Offices
            
                        Office of the Director
          Office of Management
          Office of New Animal Drug Evaluation
          Office of Surveillance and Compliance
          Office of Applied Science
          Office of Minor Use and Minor Species Home
          About FDA
          FDA Organization
          Center for Veterinary Medicine
          CVM Offices
          Office of New Animal Drug EvaluationCVM Offices Office of New Animal Drug Evaluation

    
Share
    Post
    Linkedin

    Email
    PrintEspañol

The Office of New Animal Drug Evaluation's (ONADE's) major responsibility is to review information submitted by drug sponsors who want approval to manufacture and market animal drugs. New animal drugs cannot be legally marketed unless they have been reviewed and approved, conditionally approved, or index-listed by FDA.

ONADE determines whether or not an animal drug should be approved for marketing. In order to approve and sustain a new animal drug for commercial use, four critical pillars must be met. First, an animal drug product must be **safe**, safe for the animal, safe for the humans consuming food derived from treated animals and safe for the user or the person administering the drug. Second, an animal drug must be**effective**for its intended uses. These uses are those prescribed, recommended or suggested in the labeling of the product. Third, the animal drug must be a **quality manufactured product**, being the result of a validated manufacturing process conducted in accordance with current Good Manufacturing Practice regulations. Fourth, the product must be **properly labeled**to inform the user of the product not only how to use the product but also safety considerations, residue withdrawal procedures, and storage and handling procedures. In addition, FDA considers the impact of the drug on the environment during the review process. When the regulatory standards for these pillars are met, an animal drug can be approved for marketing. Once in the market place, an animal drug is monitored to ensure that these standards are sustained. It is the responsibility of the drug sponsor (the individual or firm seeking FDA approval of the drug product) to conduct the necessary tests.

ONADE is divided into eight divisions, each charged with the evaluation or oversight of different aspects of the new animal drug review process. Effectiveness and target animal safety information is the responsibility of two divisions which evaluate drugs for food animals and companion animals, respectively, and one division which evaluates generic animal drugs. The division of animal bioengineering and cellular therapies evaluates the safety and effectiveness of certain biologic-based drugs such as cell- and tissue-based products for therapeutic use, and intentional genomic alterations in animals that are used for both therapeutic and production purposes. The division of human food safety evaluates the safety to the public by ensuring edible products derived from food-producing animals treated with new animal drugs are safe for human consumption. The division of manufacturing technologies evaluates the manufacturing processes and quality control. The division of scientific support evaluates the environmental impact and provides statistical and clinical pharmacology support across all the scientific review divisions. And to ensure ONADE operates in an efficient and effective manner, one division provides business informatics, project management, quality assurance and records management support.

If the data and information show the drug is safe, effective, quality manufactured and properly labeled ONADE recommends that the Center Director approve the application.

ONADE's review process includes the following:

Meets with sponsors in presubmission conferences to discuss development plans and reach agreement on the requirements for approval.
	Reviews submitted protocols for experimental work conducted to ensure the studies will provide the necessary information to support the approval.
	Determines the adequacy of information submitted to support approval.
	Evaluates the target animal safety and effectiveness of new animal drug products.
	Evaluates the safety for human consumption of drug residues in food derived from treated animals.
	Evaluates the impact of animal drugs on the environment.
	Evaluates manufacturing methods and procedures for new animal drug products.
	Reviews the product labeling to ensure it is accurate and not misleading.
	Prepares a Freedom of Information (FOI) summary of the information the agency relied upon to support approval.
	Coordinates the development and implementation of regulations and policies pertaining to the development of new animal drugs.Additional Resources

Office of New Animal Drug Evaluation Contact Information
	New Animal Drug Applications
	ONADE Project Managers - Our Role in the Animal Drug Approval Process

                                                                                  Content current as of:
      01/26/2024CVM Offices
            
          
                        Office of the Director
          Office of Management
          Office of New Animal Drug Evaluation
          Office of Surveillance and Compliance
          Office of Applied Science
          Office of Minor Use and Minor Species
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop